Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 2, 2010

 

 

SANGAMO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-30171   68-0359556

(Commission

File Number)

 

(IRS Employer

Identification No.)

501 Canal Blvd, Suite A100   Richmond, California 94804
(Address of Principal Executive Offices)   (Zip Code)

(510) 970-6000

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders (the “Annual Meeting”) of Sangamo BioSciences, Inc. (the “Company”) was held on Wednesday, June 2, 2010 for the purposes of (i) electing eight directors to serve on the board of directors of the Company for a one-year term; (ii) ratifying the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010; and (iii) approving the 2010 Employee Stock Purchase Plan (the “ESPP”) pursuant to which 2,100,000 shares of common stock of the Company will be available for issuance. There were present at the meeting, in person or represented by proxy, the holders of 38,823,564 shares of common stock, constituting a quorum. Stockholders passed all three proposals. The final vote on the proposals was recorded as follows:

Proposal No. 1: Election of Directors

Each of the nominees for directors listed in the proxy statement for the Annual Meeting was elected by the votes set forth in the table below:

 

Director Nominees

   Votes For    Votes Withheld    Broker
Non-Votes

Edward O. Lanphier

   18,173,029    822,648    19,827,887

Paul B. Cleveland

   18,237,533    758,144    19,827,887

Stephen G. Dilly, M.B.B.S., Ph.D.

   18,585,245    410,432    19,827,887

William G. Gerber, M.D.

   18,156,567    839,110    19,827,887

John W. Larson

   17,028,531    1,967,146    19,827,887

Steven J. Mento, Ph.D.

   18,242,933    752,744    19,827,887

William R. Ringo

   18,535,500    460,177    19,827,887

Thomas G. Wiggans

   18,194,142    801,535    19,827,887

Proposal No. 2: Ratification of Appointment of Ernst & Young LLP

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010 was ratified by the votes set forth in the table below:

 

      Votes For    Votes Against    Abstentions    Broker
Non-Votes

Ratification of Appointment of Ernst & Young LLP

   36,816,874    1,806,386    200,304    0

Proposal No. 3: Approval of ESPP

The ESPP was approved by the votes set forth in the table below:

 

      Votes For    Votes Against    Abstentions    Broker
Non-Votes

Approval of ESPP

   18,139,681    753,577    102,419    19,827,887


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2010

 

SANGAMO BIOSCIENCES, INC.
By:  

/S/    EDWARD O. LANPHIER II        

  Edward O. Lanphier II
  President, Chief Executive Officer